Key Highlights

  • VivoSim Labs (NASDAQ:VIVS) traded at USD 0.1597, up 5.07%, in pre-market trading on Tuesday, October 27, 2026. No company-specific announcement dated on or just before that day accompanied the move, which appears consistent with thin liquidity.
  • For the fiscal first quarter ended June 30, 2026, the company reported revenue of USD 18,000 and a net loss of USD 1.3 million, equal to USD 0.25 per share, per the earnings summary.
  • The company's release of Thursday, August 6, 2026 stated cash of approximately USD 10.1 million, Nasdaq compliance with the stockholders' equity rule and a reiterated expectation of fiscal 2027 revenue growth above 500%.
  • Shares outstanding rose from 3,194,295 on June 30, 2026 to 13,390,789 on August 3, 2026, so dilution and a sub-USD 1.00 price remain the central caveats. Pre-market quotes can change before the open.

The Pre-Market Move and Its Catalyst

VivoSim Labs (NASDAQ:VIVS), a San Diego based services company that tests drug candidates in three-dimensional human liver and intestine tissue models, traded at USD 0.1597, up 5.07%, in pre-market trading on Tuesday, October 27, 2026, according to a pre-market snapshot. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The most recent company disclosure reviewed is the Form 8-K of Thursday, August 6, 2026, which reported compliance with a Nasdaq equity rule, a milestone payment from Eli Lilly and Company and a July financing. The advance appears consistent with thin pre-market liquidity, in which a small number of orders can shift a low-priced quote by several points. That reading is an inference, not a reported cause.

How the Latest Results and Funding Frame the Move

For the fiscal first quarter ended June 30, 2026, VivoSim Labs reported revenue of USD 18,000 and a net loss of USD 1.3 million, or USD 0.25 per share, according to the earnings summary of that quarter. The company's release of Thursday, August 6, 2026 stated cash of approximately USD 10.1 million as of Monday, August 3, 2026. That figure reflects a USD 5.0 million milestone payment and USD 1.0 million of escrow release from Eli Lilly and Company received on Wednesday, July 22, 2026 for the earlier sale of its FXR programme, plus a financing of Friday, July 17, 2026 with gross proceeds of USD 4.0 million at USD 0.85 per underlying share. Nasdaq confirmed on Tuesday, August 4, 2026 that the company had regained compliance with the USD 2.5 million minimum stockholders' equity requirement.

Risks and What to Watch

The bull reading rests on the cash balance of about USD 10.1 million against a quarterly net loss of USD 1.3 million, and on the stated target of fiscal 2027 revenue growth above 500%, measured from a very small base. The bear reading rests on dilution: shares outstanding rose from 3,194,295 to 13,390,789 within roughly five weeks, largely through warrant exercises, and the pre-market quote of USD 0.1597 sits well below the USD 0.85 financing price, by simple arithmetic on two published figures. A price below USD 1.00 may also draw Nasdaq's minimum bid price rule into play, an inference. Liquidity and concentration in a small number of research contracts add further risk. Investors should watch the Federal Reserve decision of Wednesday, October 28, 2026 and the company's next quarterly filing, which has no announced date.

Where Things Stand

The answer is that VivoSim Labs (NASDAQ:VIVS) rose 5.07% pre-market to USD 0.1597 without a dated company announcement, which appears consistent with thin liquidity in a low-priced stock. The key number is the share count, which grew from 3,194,295 to 13,390,789 between June 30, 2026 and August 3, 2026, against cash of approximately USD 10.1 million. The next catalysts are the Federal Reserve decision of Wednesday, October 28, 2026, which follows the rate rise of Wednesday, September 16, 2026, and the company's next quarterly filing. Pre-market prices are snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.